Mumbai, India
Mumbai, India

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India; Belgium, & Surrey in the European Union; and Miami, Florida, in the United States; with manufacturing facilities in Goa , Bengaluru , Baddi , Indore , Kurkumbh , Patalganga , and Sikkim , along with field stations in Delhi, Pune, and Hyderabad. Cipla primarily develops medicines to treat cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.As of 17 September 2014, its market capitalisation was 7px517 billion , making it India's 42nd largest publicly traded company by market value. Wikipedia.


Time filter

Source Type

The present invention relates to a novel process for the synthesis of everolimus of formula (I) and intermediates thereof.


Patent
Cipla | Date: 2016-11-30

The present invention relates to method of treatment of hepatitis C using hexestrol or a derivative thereof. The methods of the present invention can be used in patients with hepatitis C administering hexestrol or a derivative thereof in combination with one or more anti-hepatitis C drugs.


Patent
Cipla | Date: 2016-11-24

Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of anagrelide or derivative thereof. The compositions include an effective amount of anagrelide or derivative thereof, in some instances combined with one or more additional agents for the treatment of pulmonary hypertension.


Patent
Cipla | Date: 2016-12-06

Methods of treating bladder cancer using terconazole are disclosed herein. Terconazole can be administered as part of a comprehensive treatment program, which can also include chemotherapy, immunotherapy, radiation therapy and/or surgical treatment.


Patent
Cipla | Date: 2016-12-16

Disclosed herein are methods of treating ovarian cancer comprising administering to a subject in need thereof an effective amount of methacycline, or a pharmaceutically acceptable salt thereof. The methacycline can be administered as part of treatment regimen, which also can include other chemo- or immune-therapies, radiation therapy, and/or surgical treatments.


The present invention relates to pharmaceutical compositions for inhalation which comprise one or more bronchodilators.


Patent
Cipla | Date: 2017-01-18

A device (20) is disclosed for dispensing a fluid supplied from an external fluid source. The device comprises a transducer (32) adapted to receive a fluid from the fluid source, and a collapsible linkage and trip link (502) coupling the transducer and the fluid source. The linkage has a collapsible joint inhibiting discharge of the fluid source when in a locked orientation. The device (20) further comprises a moveable member coupled to the linkage such that inhalation forces on the device cause the linkage to collapse thereby discharging the fluid from the fluid source. The device may further include a dose counter coupled to the fluid source for registering the amount of doses administered from the fluid source.


The present invention relates to method of treatment of hepatitis C using bufexamac or a derivative thereof. The methods of the present invention can be used in patients with hepatitis C administering bufexamac or a derivative thereof in combination with one or more anti-hepatitis C drugs.


Patent
Cipla | Date: 2017-07-05

The present invention relates to an environmentally friendly process for preparing rivaroxaban. The present invention provides a process for preparing rivaroxaban of formula I, the process comprising: reacting a compound of formula VI with a base in the presence of a solvent to form a compound of formula VII; and condensing the compound of formula VII with a compound of formula VIII or a compound of formula IX in the presence of a solvent to prepare rivaroxaban of formula I, wherein the solvent used in both steps comprises water.


The present invention discloses a novel process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts thereof and to novel intermediates which are produced during the course of carrying out the novel process.

Loading Cipla collaborators
Loading Cipla collaborators